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The high affinity translocator protein (TSPO) ligand 6-chloro-2-(4󸀠-iodophenyl)-3-(N,N-methylethyl)imidazo[1,2-a]pyridine-3-
acetamide (CLINME) was radiolabelled with iodine-123 and assessed for its sensitivity for the TSPO in rodents. Moreover
neuroinflammatory changes on a unilateral excitotoxic lesion rat model were detected using SPECT imaging. [123I]-CLINME was
prepared in 70–80% radiochemical yield. The uptake of [123I]-CLINME was evaluated in rats by biodistribution, competition,
and metabolite studies. The unilateral excitotoxic lesion was performed by injection of 𝛼-amino-3-hydroxy-5-methylisoxazole-
4-propionic acid unilaterally into the striatum. The striatum lesion was confirmed and correlated with TSPO expression in
astrocytes and activated microglia by immunohistochemistry and autoradiography. In vivo studies with [123I]-CLINME indicated
a biodistribution pattern consistent with TPSO distribution and the competition studies with PK11195 and Ro 5-4864 showed
that [123I]-CLINME is selective for this site. The metabolite study showed that the extractable radioactivity was unchanged [123I]-
CLINME in organs which expresses TSPO. SPECT/CT imaging on the unilateral excitotoxic lesion indicated that the mean
ratio uptake in striatum (lesion : nonlesion) was 2.2. Moreover, TSPO changes observed by SPECT imaging were confirmed
by immunofluorescence, immunochemistry, and autoradiography. These results indicated that [123I]-CLINME is a promising
candidate for the quantification and visualization of TPSO expression in activated astroglia using SPECT.
1. Introduction
The 18 kDa translocator protein [1] (TSPO; previously known
as the peripheral benzodiazepine receptor, PBR) has been
extensively studied for its intricate biological functions.
Although the physiological role of the TSPO is still unclear,
its primary location in the outer membrane of the mitochon-
dria and its role in the energy production, maintenance of
membrane potential, cellular respiration, and regulation of
steroidogenesis are well documented [2].
Most intriguing are the TSPO’s relatively low concentra-
tions in the CNS, particularly in microglia and astrocytes [3,
4] that upon insult become activated resulting in significant
overexpression in these cell types [5–7]. Consequently, TSPO
overexpression has been confirmed in Alzheimer’s disease
(AD), multiple sclerosis, stroke, Parkinson’s disease, HIV
encephalitis, and trauma [7–11]. The observation that TSPO
are also found in cancer cells [12] also suggests a role in
cell proliferation, malignancy, and modulation of apoptosis
[13, 14]. As a consequence the TSPO has been targeted for
both potential therapeutic applications and in imaging using
Positron Emission Tomography (PET) and Single Photon
Emission Computed Tomography (SPECT).
The isoquinoline carboxamide PK11195, radiolabelled
with tritium [3], carbon-11 [15], iodine-123/125 [16–18], and
fluorine-18 [19] have been extensively used as pharmaco-
logical probes for studying the function and expression of
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Figure 1: Structure of CLINME.
the TSPO. As a result, these compounds have been shown
to localise in areas associated with microglia activation
following a range of neurological insults [7] and a number
of PET and SPECT clinical studies have been performed
using [11C]-PK11195 [20–22] and [123I]-PK11195 [23] to detect
microglia activation in humans.
However, these radiolabelled PK11195 analogues dis-
played a significant degree of nonspecific binding in vivo [24],
a characteristic which can distort the imaging data. This has
driven research towards the development of other classes of
high affinity TSPO ligands [25–28] for use in PET and SPECT
imaging.
The acetamide structure of CLINME provides a unique
opportunity to prepare structurally diverse compounds
suitable for the incorporation of a variety of PET and SPECT
isotopes. Consequently, 𝑁󸀠,𝑁󸀠-methylethyl-6-chloro-
(4󸀠-iodophenyl)imidazo[1,2-a]pyridine-3-acetamide or
CLINME (Figure 1) has been prepared for radiolabelling with
both carbon-11 and iodine-123 for PET and SPECT studies,
respectively. We have shown that [11C]-CLINME [29, 30]
has demonstrated lower nonspecific binding than [11C]-
PK11195 and was better able to depict microglia activation
following unilateral excitotoxic lesions in rodent models
of inflammation than [11C]-PK11195 [31]. As this molecule
also incorporates iodine, it presents an excellent opportunity
to also exploit additional studies when radiolabelled with
iodine-125 for pharmacological studies as well as with
iodine-123 and iodine-124 for use in SPECT and PET
imaging, respectively. Here, we report the radiolabelling, in
vitro, in vivo pharmacological evaluation of the iodine-123
labelled analogue [123I]-CLINME and its in vivo imaging in
a model of the unilateral excitotoxic lesion using SPECT.
2. Materials and Methods
2.1. Synthesis and Characterisation of Chemical Precursors
and Standards. NMR spectra were performed on a Bruker
Avance DPX 400 operating at 400MHz for 1HNMR spectra
and 100MHz for 13C. Chemical shifts are given in ppm
(𝛿) from the internal standard tetramethylsilane in the
specified deuterated solvents. Low resolution mass spectra
were performed using either a VG Quattro triple quadrupole
mass spectrometer (Fisons Biotech MS, Altrincham, UK) in
electrospray mode or a Micromass ZMD Quadrupole Mass
Spectrometer for Electron Impact.
Melting points were performed on a Gallenkampmelting
point apparatus and are uncorrected. Elemental analysis was
performed on a Carlo Erba 1106 Elemental Analyser by
the Australian National University (Canberra, Australia) and
results were within ±0.40% of the theoretical value.
All reagents and solvents if not specified were purchased
from Sigma-Aldrich and were used without further purifi-
cation. The structures of the synthesised compounds were
confirmed by 1HNMR, 13CNMR,MS, andmicroanalysis (or
HRMS).
The synthesis of the radiolabelling precursors and stan-
dards followed the scheme in Figure 2.
2.2. 2-(6-Chloro-2-(4-iodophenyl)imidazo[1,2-a]pyridin-3-yl)-
N-ethyl-N-methylacetamide (CLINME) (1). Under a nitro-
gen atmosphere, 1,1󸀠-carbonyldiimidazole (CDI) (1.14 g,
7.0mmol) was added to a suspension of 2-(6-chloro-2-(4-
iodophenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid 4 [32, 33]
(2.32 g, 5.8mmol) in anhydrous THF (100mL) and the
resultant mixture stirred for 1 h at RT, followed by 1 h at 55∘C.
After cooling to RT, N-methylethylamine (0.38 g, 6.4mmol)
in THF (1mL) was added.Themixture was stirred for 1 h and
the solvent evaporated. The remaining residue was taken up
in CH
2
Cl
2
(100mL) and washed with 10% Na
2
CO
3
solution
(80mL) and the aqueous layer extracted with CH
2
Cl
2
(60mL
× 3). The combined organic layers were dried (Na
2
SO
4
) and
evaporated to give the crude product. Recrystallisation from
ethyl acetate gave CLINME (1).
CLINME 1 was obtained as a white solid (1.58 g, 60%)
(m.p 65–67∘C). 1HNMR (CDCl
3
): (Rotamers 1 : 1) 𝛿 1.06 and
1.13 (t, J = 7.2Hz, 3H, CH
3
), 2.95 (s, 3H, CH
3
), 3.29 and 3.35 (q,
J = 7.2Hz, 2H, CH
2
), 4.03 and 4.06 (s, 2H, CH
2
), 7.17 and 7.18
(dd, J = 9.5, 1.9Hz, 1H), 7.38 and 7.39 (d, J = 8.4Hz, 2H), 7.56
(dd, J = 9.5, 0.8Hz, 1H), 7.8 (d, J= 8.4Hz, 2H), 8.21 and 8.23
(J = 1.8, 0.8Hz, 1H). 13C NMR (CDCl
3
) d: 12.31, 13.52, 29.66,
30.11, 33.15, 35.05, 43.06, 44.74, 93.94, 93.97, 115.35∗, 117.75∗,
120.59, 120.64, 122.48, 122.54, 126.03, 126.08, 130.25∗, 133.69,
133.76, 137.82∗, 143.6, 143.61, 143.92, 144.01, 167.03, 167.1. (Note:
doublets in carbon spectrum are due to restricted rotation
(Rotamers). The numbers with ∗ are the only carbons not
appearing as doublets.) MS: m/z: 456 (32% [M+H]+), 454
(100%, [M+H]+). Anal. (C
18
H
17
N
3
OClI) C, H, N.
2.3. 2-(2-(4-Bromophenyl)-6-chloroimidazo[1,2-a]pyridin-3-yl)-
N-ethyl-N-methylacetamide (2). Under a nitrogen To DMF
(30mL) under nitrogen atmosphere, were added 2-(2-(4-
bromophenyl)-6-chloroimidazo[1,2-a]pyridin-3-yl)acetic acid
5 [32, 33] (1.0 g, 2.73mmol), N-methylethylamine (0.2 g,
3.38mmol), 4-methylmorpholine (NMM, 1.1 g, 10.9mmol), 1-
hydroxybenzotriazole (HOBT, 0.52 g, 3.38mmol), and N-(3-
imethylaminopropyl-N󸀠–ethylcarbodiimide (EDCI, 0.63 g,
4.05mmol) and then stirred at RT for 24 h. Brine (30mL) was
added and the mixture extracted with ethyl acetate (75mL ×
2). The organic layer was dried (Na
2
SO
4
), filtered, and
evaporated to dryness.The solid was triturated with 1 : 5 ethyl
acetate/petroleum spirit, filtered, and dried in vacuo to obtain
(2).
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Figure 2: Synthesis of CLINME and stannane precursor (from bromo) for radiolabelling: (a) for 1, N-methylethylamine, CDI, and THF at
55∘C, for 2 N-methylethylamine, EDC, HOBT, in DMF at RT (b) Sn
2
(Bu)
6
, Pd(PPh
3
)
4
in toluene at reflux.
The bromo analogue 2 was obtained as a tan coloured
solid (0.61 g, 55%) (m.p 159-160∘C). 1H NMR (CDCl
3
):
(Rotamers 1 : 1) 𝛿 1.07 and 1.12 (t, J = 7.2Hz, 3H, CH
3
), 2.95
(s, 3H, CH
3
), 3.28 and 3.44 (q, J = 7.2Hz, 2H, CH
2
), 4.03 and
4.07 (s, 2H, CH
2
), 7.17 and 7.18 (m, 1H, CH), 7.51–7.61 (m,
5H, 4 × ArCH and 1 CH, superimposed), 8.23 (m, 1H, CH).
MS (ES+ve) m/z: 410 ([M+H]+ C
18
H
17
N
3
O81Br37Cl),
408 ([M+H]+ C
18
H
17
N
3
O81Br35Cl) and ([M+H]+
C
18
H
17
N
3
O79Br37Cl), 406 ([M+H]+ C
18
H
17
N
3
O79Br35Cl).
13C NMR (DMSO) d: (12.32, 13.35), (28.41, 28.99), (32.55,
34.50), (42.1, 43.86), 117.42, (117.45, 117.49), (118.82, 118.87),
(121.00, 121.06), (125.28, 125.33), (129.66, 129.73), 131.60,
(133.43, 133.46), (142.31, 142.34), (142.35, 142.42), 167.18 (note:
numbers in parentheses indicate Rotamer pair).
2.4. 2-(6-Chloro-2-(4-(tributylstannyl)phenyl)imidazo[1,2-a]
pyridin-3-yl)-N-ethyl-N-methylacetamide (3). To a solution
of (2) (0.4 g, 0.98mmol) in toluene (20mL) were added
hexabutylditin (0.86 g, 1.48mmol) and a catalytic amount
of palladium(0) tetrakis(triphenylphosphine) (30mg,
0.026mmol). The reaction mixture was heated to reflux
for 40 h, cooled, and filtered through celite and the filtrate
evaporated to dryness. The resulting brown residue was
purified on silica gel eluting firstly with 10% petroleum ether/
ethyl acetate followed by 40% petroleum ether/ethyl acetate
to give the title compound (3).
The stannane labelling precursor 3 was obtained as a
yellow oil (0.3 g, 50%). 1H NMR (CDCl
3
): 𝛿 (Rotamers ∼
55 : 45) 0.88−1.60 (m, 30H, Bu-H and CH
3
, superimposed);
2.95 (s, 1.65H, N-CH
3
), 2.96 (s, 1.35H, NCH
3
); 3.26 (q, J =
7.2Hz, 1.1H, N-CH
2
), 3.46 (q, J = 7.2Hz, 0.9H, N-CH
2
); 4.10
(s, 0.9H, CH
2
), 4.13 (s, 1.1H, CH
2
), 7.30 (m, 1H, CH), 7.61 (s,
4H, ArCH × 4), 7.83 (m, 1H, CH), 8.32 (s, 0.45H, CH), 8.36
(s, 0.55H, CH). MS (ES+ve) m/z: major peak 618 ([M+H]+
C
30
H
44
N
3
O35Cl120Sn).
2.5. Radiochemistry Analytical Methods. Semipreparative
radio-High Pressure Liquid Chromatography (HPLC) was
performed on a Berthold LB501 system equipped with a
Waters 510 pump, a Spectrophysics-Linear UV detector, set at
254 nm, and an online NaI-Berthold radioactivity 𝛾-detector,
using a Phenomenex Bondclone C18 column (10𝜇m, 300 ×
7.8mm). The analytical HPLC system was equipped with a
Varian 9002 pumpwith a Spectrophysics-Linear UV detector
set at 230 nm and 254 nm and an Acemate 𝛾-detector using
a Phenomenex Synergi hydro C18 column (4𝜇m 250 ×
4.6mm).
2.6. Radiolabelling and Quality Control of [123/125I]-CLINME.
The tributyltin precursor (0.25mg, 0.40 𝜇mol) in acetic acid
(100 𝜇L) was treated with a solution of Na123I (ANSTO
Health) or Na125I (GE-Healthcare) (0.5–1.1 GBq) followed by
peracetic acid (32%, 50 𝜇L). After 5min the solution was
quenched (Na
2
S
2
O
5
) (4.9mg, 30 𝜇mol, in 100 𝜇L H
2
O), neu-
tralised with NaHCO
3
(5.5mg, 65 𝜇mol, in 100 𝜇LH
2
O), and
diluted with mobile phase (300𝜇L). The resulting mixture
was purified by semipreparative radio-HPLC, eluting with a
mobile phase consisting of acetonitrile : ammonium acetate
(0.01M) (50 : 50) at a flow rate of 4mL/min. For radiochem-
ical purity and stability measurements, the radioiodinated
solution was ascertained on an analytical HPLC system,
eluting with acetonitrile : 0.1M ammonium acetate (60 : 40)
at a flow rate of 1mL/min.
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2.7. Lipophilicity. The log𝑃 values were estimated by compar-
ing HPLC retention times of test compounds with retention
times of standards having known log 𝑃 values as described
[34].
2.8. Biological Evaluation. All in vivo experimental proce-
dures were carried out in compliance with Australian laws
governing animal experimentation.
2.9. In Vitro Binding Assays. Inhibition constant (IC
50
) of
CLINME for the TPSO and for the central benzodiazepine
receptor (CBR) was determined as described previously [35].
The IC
50
values were converted to the inhibition constant, Ki,
using Cheng-Prusoff equation.
2.10. In Vivo Biodistribution Studies. No carrier added [123I]-
CLINME (0.7MBq, 10 pmoles) dissolved in 0.9% saline
(0.1mL) was administered to 8–10-week-old male Sprague-
Dawley (SD) rats (𝑛 = 4–6) via tail vein injection in a
volume of 0.1mL. At 5, 15, and 30min and 1, 3, and 6 h after
injection (p.i.) of the [123I]-CLINME, the rats were sacri-
ficed by CO
2
administration followed by cervical fracture.
Peripheral organs (including liver, spleen, thyroid, pancreas,
lung, heart, kidney, adrenals, and blood), olfactory bulbs, and
the remainder of the brain were removed. Samples of organs
and tissues were weighed and the radioactivity was measured
using an automated 𝛾-counter. The percent of injected dose
(%ID) was calculated by comparison to a diluted standard
solution derived from the initial injected sample. Radioactiv-
ity concentrations were expressed as percent of injected dose
per gram of wet tissue (% ID/g).
2.11. Pharmacological Competition Studies. The saturation
effect of [123I]-CLINME uptake was studied in competition
experiments by injecting CLINME (1mg/Kg), 5min prior to
[123I]-CLINME (0.7MBq, 10 pmoles in 0.1mLof 0.9% saline),
via the tail vein, to 8–10-week-old male SD rats.
The in vivo specificity of [123I]-CLINME uptake in rats
was investigated in competition experiments using flumaze-
nil (CBR selective drug), Ro 5-4864, and PK11195 (TPSO
selective drugs) (1mg/Kg). The drugs were dissolved in
dimethyl sulfoxide/saline (1 : 5) and injected intravenously
5min prior to [123I]-CLINME. Groups of rats (𝑛 = 3-4)
were sacrificed by CO
2
administration followed by cervical
fracture 30min after administration of [123I]-CLINME and
peripheral organs (liver, spleen, lung, heart, kidney, and
adrenals), blood, olfactory bulbs, and the remainder of the
brain were removed. The radioactivity concentrations were
calculated as described previously. Results were analysed
by one-way analysis of variance (ANOVA) followed by
Tukey’s post hoc test for comparing the tissue radioactivity
concentrations in the treated animals (𝑛 = 3-4) and in the
controls (𝑛 = 6). The criterion for significance was 𝑃 < 0.05.
2.12.Metabolite Studies. Groups ofmale SD rats were injected
with [123I]-CLINME (7.4MBq in 0.1mL of 0.9% saline) and
sacrificed at 15, 60, and 180min p.i. Adrenals, kidney, heart,
and brain were quickly excised.
Tissue fractions (200mg) were treated with acetonitrile
(2mL) and homogenised, and the mixture was centrifuged at
2,000 rpm. The supernatant was removed and the pellet was
treated for a second time, as above and the combined super-
natants concentrated to 50 𝜇L. Plasma (0.2mL) separated
from blood was extracted with acetonitrile and concentrated.
The concentrated extracts were applied onto silica gel C18
plates with a preconcentration zone (Merck, Darmstadt,
Germany) and developedwith ethyl acetate.The radioactivity
distribution was measured using a static radiochromatogram
analyser (Berthold Co.).
2.13. Unilateral Excitotoxic Lesion. Lesioning was performed
by stereotaxically injecting 7.5 nmol 𝛼-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) unilaterally into
the striatum. Male SD rats (317 ± 56 g) were anaesthetised
with inhaled isoflurane in O
2
(5% induction, ∼2% main-
tenance thereafter) and positioned in a stereotaxic frame
(Stoelting Co., USA). A 1.5 cm incision was made in the scalp
to reveal the skull surface and a burr hole was drilled over the
injection site. Animals were injected with AMPA (15mM) in
a volume of 0.5 𝜇L of 0.9% saline using a Hamilton syringe
in a microinfusion pump (KD Scientific Co., USA) at a rate
of 0.5 𝜇L/min (𝑛 = 5, coordinates: AP = +0.7mm and L =
±2.7mm (left 𝑛 = 2, right 𝑛 = 3), relative to bregma;
DV = −5.5mm from dura) [36]. Following the injection, the
needle was left in situ for a further 5min to allow the fluid
to disperse. After the needle was withdrawn, the incision was
sutured and cleansed. Animals were given a week to recover
prior to imaging. Analgesia was provided by subcutaneous
administration of 0.05mg/Kg buprenorphine.
2.14. SPECT Imaging. Two hours prior to [123I]-CLINME
administration, thyroid blocking was performed with an
intraperitoneal injection of 2mg/Kg potassium iodide. [123I]-
CLINME (74–148MBq in 0.1mL of 0.9% saline, S.A. >
80GBq/𝜇mol) was injected via the tail vein. One hour p.i.,
the animals were imaged on a dual-head 𝜇-SPECT system
(GammaMedica, USA) equipped with medium-energy pin-
hole collimators (focal length 90.0mm, aperture diameter
1.5mm), under isoflurane anaesthesia (1-2% in O
2
). Two
acquisitions (each of 64 projections, 60 seconds per projec-
tion, 4.5 cm ROR) were performed sequentially. The energy
windowwas 20%, centred over 159 keV. Following the SPECT,
an X-ray Computed Tomography (CT) scan was performed
(voltage 70 kVp).
SPECT volumes were reconstructed with an Ordered
Subset Expectation Maximisation iterative reconstruction
algorithm using 3 iterations and 8 subsets. Due to the
expected low-level of activity in the brain, as a function of
the known low-level of TSPO in the CNS, a 20x scaling
was applied to the SPECT images post hoc to maximise
the dynamic range. The SPECT and CT volumes were
coregistered, displayed, and analysed using Anatomist visual-
isation software [37]. An ipsilateral volume of interest (VOI,
24.4mm3) was created in the dorsal striatum, using the CT-
visualised burr hole as a landmark, and a corresponding VOI
placed on the contralateral side as the control region. At
each of the time points p.i., the ratio of the mean activity
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in the lesion VOI compared to the contralateral control
VOI was determined. The data were compared using the
nonparametric Mann-Whitney U test with a 𝑃 value < 0.05
considered significant.
Following imaging, the animals were euthanised by CO
2
administration and the brains removed and frozen with
liquid nitrogen. Tissue was stored at −80∘C, cut (20 𝜇m), and
mounted onto poly-L-lysine coated slides and then stored at
−80∘C until use for autoradiography and immunohistochem-
istry.
2.15. Autoradiography. Autoradiography with [125I]-
CLINME was performed on brain tissue. Nonspecific
binding was assessed by coincubating the slides with 20 𝜇M
of either PK11195 or CLINME. The specificity of [123I]-
CLINME for the TSPO was assessed by coincubating slides
with flumazenil (20𝜇M). Sections were incubated at RT for
1 h in 100mM Phosphate-Buffered Saline (PBS, pH 7.4, and
0.9%NaCl) containing 16 nM [125I]-CLINME, either alone or
with 20𝜇M of one of the drugs above. They were then rinsed
twice in ice-cold buffer and once in distilled H
2
O, dried
overnight, exposed for 3 h to film (Hyperfilm, Amersham
Biosciences, UK; Kodak Biomax MR, Sigma-Aldrich, USA),
then developed, fixed, and dried.
Images were digitised and analysed using MCID image
analysis software. To allow comparison with the SPECT
images, a 2D region of interest (ROI) was placed over
the dorsal striatum, with corresponding ROI placed on
the contralateral side as a control region, the square ROIs
having the same area as one facet of the cubic VOIs used
to analyse the SPECT images. The mean relative optical
density (ROD) was then determined in each region. Mean
ROD in the ipsilateral versus the control ROI within each
of the 4 incubation conditions ([125I]-CLINME alone or
coincubated with one of the 3 blocking drugs) was compared
using the nonparametric Mann-Whitney U test. Differences
between the coincubated slides and those incubated with
[125I]-CLINME alone were compared separately for lesion
and control ROIs using the nonparametric Kruskal-Wallis
test and post hoc Mann-Whitney U tests. A 𝑃 value < 0.05
was considered significant.
2.16. Immunohistochemistry and Immunofluorescence.
Immunohistochemistry was performed in the same manner
as described by Boutin et al. [31]. Sequential sections of
tissue, adjacent to those used for autoradiography, were
stained either for glial fibrillary acidic protein (GFAP) and
CD11b antigen (Ox42) or for GFAP and neuron-specific
nuclear protein (NeuN). Sections were fixed in 10% formalin
(Sigma-Aldrich, USA) for 1 h, washed in 6 × 5min PBS,
and then incubated for 20min in diluent (PBS with 5%
normal horse serum and 0.1% Triton X-100). Sections were
then incubated overnight at 4∘C with primary antibodies in
diluent (rabbit anti-cow GFAP, 1 : 1,000, DakoCytomation;
mouse anti-rat CD11b, 1 : 1,000, Serotec; mouse anti-mouse
NeuN, 1 : 1,000, Chemicon) and then washed in 3 × 5min
PBS. Incubation in secondary antibodies was for 1 h at RT
(Alexa Fluor 594 nm goat anti-mouse IgG, 1 : 500; Alexa
Fluor 488 nm goat anti-rabbit IgG, 1 : 500 (Molecular Probes,
Invitrogen)) and then sections were washed again in 3 ×
5min PBS. Sections were mounted with an antiadherent
solution (Citifluor, UK). Sections incubated without primary
antibodies served as negative controls.
Immunofluorescence images were obtained with an
Olympus BX-41 microscope equipped with a digital camera
(QImaging, Canada) at 10x magnification, acquired with
Image-Pro software. Image fusionwas performedwithMCID
image analysis software.
3. Results
3.1. Lipophilicity. The lipophilicity of CLINME was ascer-
tained to understand the in vivo uptake of [123I]-CLINME.
The CLINME log P
7.5
value was 3.27 in comparison with the
log P
7.5
of PK11195 that was 3.35.
3.2. In Vitro Binding Assays. Data from the binding assays on
membranes from kidney and brain cortex gave 𝐾
𝑖
values for
the TSPO of 1.6 ± 0.2 nM ([3H]-PK11195) and 4.5 ± 0.6 nM
([3H]-Ro 5-4864). The inhibition constant for the CBR was
183 ± 20 nM.
3.3. Radiolabelling. [123/125I]-CLINME was prepared by elec-
trophilic substitution of the tributyltin precursor with
123/125I-NaI in acetic acid using peracetic acid as the oxi-
dant followed by HPLC purification. [123/125I]-CLINME was
eluted with a retention time 𝑘󸀠 = 14min in a radiochemical
yield of 74 ± 5% (𝑛 = 8) and 86 ± 8% (𝑛 = 4) for [123I]-
and [125I]-CLINME, respectively. Radiochemical purity as
assessed by analytical HPLC was >99% and the specific
activity (SA) for [123I]-CLINME was >185GBq/𝜇mol based
on the limit of detection of the HPLC system. The SA for
[125I]-CLINME was measured as 80GBq/𝜇mol close to the
theoretical specific activity of the 125I-iodine. [123I]-CLINME
was reconstituted in saline for in vivo pharmacological
studies. The radiochemical purity of [123]-CLINME in saline
at room temperature, 3 h after synthesis, was >97% whereas
[125I]-CLINME was stable (>97%) for up to 6 weeks in
ethanol when stored at −80∘C.
For in vitro assays, CLINME was added to the [125I]-
CLINME to achieve a specific activity of 3.7 GBq/𝜇mol and
reconstituted in ethanol.
3.4. Biodistribution. Table 1 summarises the tissue time
course distribution of [123I]-CLINME in rats. In the periph-
eral organs, a plateau was observed in the adrenals after
30min to 6 h p.i. (≈7.5% ID/g). In liver, spleen, kidney, heart,
and lung the activity peaked (0.7, 2.7, 1.8, 3.5, and 7.9% ID/g) at
5 or 15min p.i. and decreased over time to less than 0.7% ID/g
at 6 h. Very low concentrations of [123I]-CLINMEwere found
in blood (<0.18% ID/g) throughout the time ofmeasurement.
In the olfactory bulbs (0.38–0.17%), a significantly higher
concentration of the radioactivity was found compared to the
remainder of the brain (0.2–0.02%), with ratios increasing
from 2 at 5min to 8 at 6 h.The uptake in the thyroid increases
from 5min to 1 h (4–7%) and then a decrease was observed
at 3 h to 4% which remained constant till 6 h.
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Table 1: Biodistribution of [123I]-CLINME in SD male rats.
%ID/g 5min 15min 30min 1 hour 3 hours 6 hours
Liver 0.70 ± 0.10 0.68 ± 0.07 0.51 ± 0.07 0.42 ± 0.07 0.23 ± 0.01 0.21 ± 0.05
Spleen 2.00 ± 0.55 2.65 ± 0.40 2.21 ± 0.15 1.76 ± 0.12 1.02 ± 0.14 0.67 ± 0.09
Kidney 1.82 ± 0.20 1.75 ± 0.07 1.78 ± 0.18 1.16 ± 0.18 0.70 ± 0.05 0.51 ± 0.09
Lungs 7.88 ± 0.62 3.53 ± 0.44 2.45 ± 0.30 1.68 ± 0.10 0.95 ± 0.12 0.68 ± 0.08
Heart 3.28 ± 0.30 3.53 ± 0.23 3.32 ± 0.31 2.601 ± 0.13 1.28 ± 0.13 0.72 ± 0.14
Blood 0.18 ± 0.02 0.09 ± 0.01 0.08 ± 0.01 0.06 ± 0.00 0.04 ± 0.00 0.03 ± 0.00
Brain 0.20 ± 0.02 0.10 ± 0.01 0.08 ± 0.00 0.06 ± 0.01 0.03 ± 0.00 0.02 ± 0.00
Olfactory bulbs 0.38 ± 0.03 0.28 ± 0.04 0.34 ± 0.01 0.26 ± 0.05 0.25 ± 0.01 0.17 ± 0.05
Thyroid 4.62 ± 2.17 5.62 ± 1.24 7.37 ± 2.14 6.46 ± 2.26 3.41 ± 1.10 4.11 ± 1.15
Adrenals 2.89 ± 0.48 4.71 ± 0.26 7.55 ± 1.38 6.77 ± 0.54 6.65 ± 0.56 8.34 ± 0.71
Results are mean ± SD percent of injected dose per gram (%ID/g), 𝑛 = 3-4 rats.
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Figure 3: Effect of competing drugs (CLINME, PK11195, Ro 5-4864,
and flumazenil, 1mg/Kg) on [123I]-CLINME uptake in CNS and
blood of normal rat. Results are average of 3–6 rats ± SD, 30min p.i.
of [123I]-CLINME. Unit is percent injected dose per gram (%ID/g)
(∗∗𝑃 < 0.01, ∗𝑃 < 0.005).
3.5. Pharmacological Competition Studies. The saturating
effect of CLINME (1mg/Kg) was observed with high sig-
nificant decreases in the heart, kidney, lungs, and olfactory
bulbs by 86, 71, 76, and 38% (𝑃 < 0.01), respectively. A
nonsignificant reduction of uptake was also observed in the
adrenals. A significant increase (𝑃 < 0.01) of [123I]-CLINME
uptake was observed in the blood (45%).
Drug competition experiments were carried out to test
the ability of TSPO and CBR drugs to inhibit [123I]-CLINME
uptake in the brain and in peripheral organs (Figures 3 and
4). PK11195 was the most potent in inhibiting the uptake of
[123I]-CLINME in the heart, lungs, and kidney by 87, 81, and
72% (𝑃 < 0.01), respectively, compared to control animals. A
significant decrease (𝑃 < 0.05) of 36% was also observed in
the olfactory bulbs. A nonsignificant reduction was observed
in the adrenals. With this drug, the uptake of [123I]-CLINME
in blood was significantly increased by 29% compared to
controls (𝑃 < 0.01). Ro 5-4864 also significantly reduced
the uptake of activity in the heart, kidney, lungs, and the
remainder of the brain by 77, 68, 62, and 23% (𝑃 < 0.01),
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Figure 4: Effect of competing drugs (CLINME, PK11195, Ro 5-4864,
and flumazenil, 1mg/Kg) on [123I]-CLINME uptake in peripheral
organs of normal rat. Results are average of 3–6 rats ± SD, 30min p.i.
of [123I]-CLINME. Unit is percent injected dose per gram (%ID/g)
(∗∗𝑃 < 0.01).
respectively. A nonsignificant reduction was observed in the
olfactory bulbs. The reduction of uptake of [123I]-CLINME
in the blood was not significant, while the concentration in
the adrenals was significantly increased by 73% compared
to controls (𝑃 < 0.01). With flumazenil nonsignificant
differences of [123I]-CLINME uptake in peripheral organs
and brain were observed.
3.6. Metabolite. The time course of unchanged [123I]-
CLINME was studied in adrenals, kidney, brain, heart, and
olfactory bulbs as well as in plasma.With the homogenisation
technique used in this experiment, more than 85% of the
activity from tissues and plasma was extracted into acetoni-
trile and analysed by radio thin layer chromatography. In the
adrenals, kidney, and heart, more than 95% of the extractable
radioactivity was shown to be unchanged [123I]-CLINME,
which remained constant over the three hours studied.
Brain tissue, even the low activity present, represents >95%
of unchanged radiotracer. In plasma, metabolite analysis
showed that 15, 5, and 2% of the extracted activity were
unchanged tracer, 15min and 1 and 3 h p.i., respectively.
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Figure 5: SPECT images of [123I]-CLINME uptake in the unilateral
excitotoxic lesion ratmodel.The red square represents the volume of
interest (VOI) used to sample the activity. A corresponding region
was drawn on the contralateral side as a control (region not shown).
3.7. SPECT Imaging. SPECT imaging with [123I]-CLINME
showed a significantly higher signal in the area of the
lesion than in the corresponding control striatum at
both time points p.i. (Figure 5). The mean ratio ± SD
(ipsilateral : contralateral) found with SPECT at 60min p.i.
was 2.18 ± 0.89 and 1.86 ± 0.51 at 120min p.i.
3.8. Autoradiography. In tissue harvested immediately fol-
lowing SPECT imaging, autoradiography with 16 nM [125I]-
CLINME also showed significantly increased radioligand
binding in the lesioned striatum compared to the con-
tralateral one (Figure 6). This differential in [125I]-CLINME
binding was eliminated by coincubation of [125I]-CLINME
with 20𝜇Mof either CLINMEor PK11195. Coincubationwith
20𝜇M flumazenil on the other hand had no effect on the
differential binding of [125I]-CLINME. Analysis of the ipsi-
lateral data across the different incubation conditions shows
that the two TSPO drugs greatly and significantly decreased
the measured ROD in these ROIs, whilst coincubation with
flumazenil produced a small, nonsignificant reduction. In the
contralateral striatum, all 3 coincubation conditions resulted
in significantly decreased ROD compared to incubation with
16 nM [125I]-CLINME alone, although these decreases were
of a smaller magnitude than those observed ipsilaterally.
3.9. Immunohistochemistry. Immunohistochemistry using
primary antibodies targeting astrocytes (GFAP), microglia
(Ox42), and neurons (NeuN) demonstrated the presence of
the excitotoxic AMPA lesionwith a pattern of staining consis-
tent with that reported in the earlier ([11C]-CLINME) study
with this same model [31]. Tissue harvested immediately
following SPECT imaging stained strongly throughout the
imaged contralateral striatum for NeuN. In the medial part
of the ipsilateral striatum NeuN staining was still present;
however it was almost completely absent centrally. GFAP
staining in these animals was present in both hemispheres,
though it was moderately increased on the lesioned side,
whilst Ox42 staining was barely perceptible in most regions,
except in the region where NeuN immunoreactivity was
virtually absent (Figure 7).
4. Discussion
In the present study we have prepared, radiolabelled, and
evaluated in vivo the novel imidazopyridine derivative,
CLINME, to determine its selectivity for the TPSO. In vitro
studies found that CLINME displayed a 110-fold higher
selectivity for the TPSO over the CBR compared to a 20-
fold difference to the related compounds, alpidem [38], and
200-fold for CLINDE [35]. Furthermore the presence of the
iodine atom and theN-methyl group on the imidazopyridine
structure presented the opportunity for radiolabelling with
either radioiodine or carbon-11 without loss in affinity or
selectivity for the TPSO,making this analogue useful for both
PET and SPECT imaging.
In vivo the distribution of radioactivity after injection of
[123I]-CLINME follows the distribution of the TPSO reported
in the literature with high uptake in endocrine tissues, such
as adrenal glands [39], in peripheral organs such as kidney
and heart [17, 40] and low uptake in the brain [41, 42]. In the
brain, the highest density of TPSO reported is in the olfactory
bulbs [4]; this correlates with the results obtained with [123I]-
CLINDE [43] and other radiolabelled radiotracers belonging
to the N-benzyl-N-(2-phenoxyaryl)-acetamide series (DAA
tracers) [44, 45].The ratio of uptake of [123I]-CLINME in the
olfactory bulbs versus the rest of brain increased from 2- to 8-
fold between 5min and 6 h; this ratio is more than twice that
reported for [18F]FE-DAA1106 of 3.5 and comparable with
[123I]-CLINDE (6 at 8 h). The uptake in the olfactory bulbs
is also always much higher than that of the blood (ratio 6 : 1)
indicating that the uptake in the brain is not due to blood flow
but to binding to TPSO sites. In addition, metabolite analysis
confirmed that the uptake in the brain was due to intact
[123I]-CLINME. These results indicated that [123I]-CLINME
crosses the brain-blood barrier (BBB), a prerequisite for brain
imaging.
The pharmacological competition studies confirm that
the uptake in the olfactory bulbs and peripheral organs could
be blocked by PK11195, Ro 5-4854, and CLINME indicating
that the uptake was specific to TPSO binding sites. However,
the uptake in the adrenals could not be blocked by CLINME
or PK11195 (1mg/Kg) whereas an increase in uptake was
foundwithRo 5-4864.These observations could be attributed
to the much higher density of TPSO in the adrenals, the
amount of competing drugs used (since a dose response
curve was not determined, it is possible that a higher dose
than 1mg/Kg might result in greater inhibition of uptake),
or the decreased availability of TSPO binding sites for [123I]-
CLINME in the peripheral organs that are occupied by
the competing drugs. This observation was also found with
carbon-11 and fluorine-18-labelled analogues belonging to
the dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA)
series [46] whereas other studies using labelled quinoline
carboxamides suggested that the uptake in the adrenals
was nonspecific [47]. Gildersleeve et al. reported a dose of
5mg/Kg of PK11195 to block the uptake of [123I]-PK11195 by
85% in the adrenals of rats [17] and Mattner et al. reported
a dose of 10mg/Kg to block the uptake of [123I]-CLINDE by
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Figure 6: Measures of relative optical density (ROD) following in vitro autoradiography with 16 nM [125I]-CLINME and effect of 20 𝜇M of
PK11195, CLINME, or flumazenil (a). Representative autoradiograms showing a region of very high activity in the unilateral dorsal striatum
(with extension dorsally into the cortex). Specific binding in the lining of the lateral ventricles can also be observed (b). ∗𝑃 < 0.05 ipsilateral
versus contralateral; §𝑃 < 0.05 versus [125I]-CLINME alone.
Figure 7: Immunohistochemistry for glial fibrillary acidic protein
(GFAP, green) and anti-CD11b antibody (Ox42) or neuron-specific
nuclear protein (NeuN, both red). The arrows indicate a region
identified as the excitotoxic lesion, with increased Ox42 staining
and decreased NeuN staining indicating microglial activation and
neurodegeneration, respectively. LV = lateral ventricle, CC = corpus
callosum.
51% [43]. As expected flumazenil was unable to inhibit the
uptake of [123I]-CLINME in peripheral organs or CNS.
The novel TSPO radioligand, [123I]-CLINME, was also
investigated in a rat model of neuroinflammation following
excitotoxic lesioning of the striatum. In previous PET studies
[11C]-CLINME was shown to be superior to [11C]-PK11195
[30, 31]; similarly the [123I]-CLINME SPECT analogue
showed comparable results in the same animal model, which
was confirmed with immunohistochemistry (Figure 7). The
ratio of [123I]-CLINME observed in the lesion versus con-
tralateral striatum (2.18 ± 0.89) was consistent with that
found in the same animal model with [11C]-CLINME PET
(2.14 ± 0.09) and considerably higher than [11C]-PK11195
(1.62 ± 0.05) [31].
The high relative accumulation of [123I]-CLINME in
the lesion versus contralateral striatum visualised with
SPECT was observed with in vitro autoradiography of [125I]-
CLINME alone (Figure 6).The differential accumulation was
eliminated by coincubationwith TSPO ligands, but not by the
flumazenil. Confirming this, analysis of the ipsilateral (lesion)
ROIs showed sections coincubated with the TSPO ligands,
but not flumazenil, to have significantly lower RODs than
those in sections incubated with [125I]-CLINME alone.
The large increase in TPSO expression associated with
the lesion, as demonstrated by [123/125I]-CLINME, was colo-
calised with the large increase in CD11b expression, moderate
increase in GFAP, and large decrease in NeuN visualised with
immunohistochemistry (Figure 7). CD11b is a 𝛽-2 integrin,
present in resting microglia, which is known to have greatly
increased expression following microglial activation [48]. In
turn, microglial activation is the primary source of increased
TSPO density following the neurological insult, as opposed
to reactive astrocytes (which were demonstrated here with
GFAP to be moderately increased) [5, 7]. The loss of NeuN
indicates neuronal loss subsequent to the excitotoxic AMPA
infusion. Taken together, it is strongly suggested that the
putative increase in TSPO expression demonstrated with
SPECT and autoradiography was due to activated microglia
induced by AMPA infusion, though it cannot be ruled out
that some proportion of the TSPO number in the lesion site
was due to invasion of peripheral TSPO expressing immune
cells across a compromised BBB [49] and CD11b [48]. The
possibility of BBB being compromised was addressed in the
PET study of [11C]-CLINME in this animal model which
showed, via assessment of Evan’s Blue extravasation in a
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parallel group of animals, that the BBB was intact 7 days after
AMPA administration to the striatum [31].
The present study has demonstrated that SPECT with
[123I]-CLINME is able to provide visualisation of a uni-
lateral excitotoxic lesion with a sensitivity similar to that
reported for PET with [11C]-CLINME. The uptake ratio
that both radioligands provided between the lesion and the
contralateral control tissue, as imaged with their respective
technologies, was superior to that found with [11C]-PK11195
PET in this model [31]. These results indicate that [123I]-
CLINME may be a very useful radiotracer for the SPECT
imaging of microglial activation associated with various neu-
ropathologies. The rapidity of microglia activation following
a variety of neurological insults and the sensitivity of this
process to even subtle changes in addition to its implication
in many pathogenic processes prompts the in vivo imaging of
microglia activation with TSPO.
5. Conclusion
[123/125I]-CLINME can be conveniently prepared via an
iododestannylation reaction in high specific activity suitable
for imaging microglial activation. In vitro studies confirmed
that CLINME exhibits high affinity and selectivity for the
TSPO. In vivo, [123I]-CLINME indicated a biodistribution
pattern consistent with known TPSO distribution with high
selectivity for the TSPO as demonstrated by competition
studies with PK11195 and Ro 5-4864. Furthermore, imaging
studies showed that [123I]-CLINME, in an AMPA induced
excitotoxic model, is a promising new radiotracer for the
quantification and visualization of TPSO expression in acti-
vated microglia with SPECT. Finally, CLINME is a versatile
radiotracer that can be prepared for PET (11C/124I) or SPECT
(123I) imaging as well as for biochemical and pharmacological
studies using the 125I-analogue.
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